Abstract:In multiple sclerosis (MS), chronic demyelination initiated by immune-mediated destruction of myelin, leads to axonal damage and neuronal cell death, resulting in a progressive decline in neurological function. The development of interventions that potentiate remyelination could hold promise as a novel treatment strategy for MS. To this end, our group has demonstrated that neural precursor cells (NPCs) residing in the ventricular-subventricular zone (V-SVZ) of the adult mouse brain contribute significantly to remyelination in response to central nervous system (CNS) demyelination and can regenerate myelin of normal thickness. However, aging takes its toll on the regenerative potential of NPCs and reduces their contribution to remyelination. In this study, we investigated how aging influences the contribution of NPCs to oligodendrogenesis during the remyelination process and whether the delivery of growth factors into the brains of aged mice could potentiate the oligodendrogenic potential of NPCs. To enable us to map the fate of NPCs in response to demyelination induced at different postnatal ages, ; mice were gavaged with tamoxifen at either 8 weeks, 30 weeks or one year of age before being challenged with cuprizone for a period of six weeks. Using osmotic minipumps, we infused heparin-binding EGF-like growth factor (HB-EGF), and/or epidermal growth factor (EGF) into the cisterna magna for a period of two weeks beginning at the peak of cuprizone-induced demyelination (n=6-8 mice per group). Control mice received artificial cerebrospinal fluid (vehicle) alone. Mice were perfused six weeks after cuprizone withdrawal and the contribution of NPCs to oligodendrocyte regeneration in the corpus callosum was assessed. Our data reveal that although NPC-derived oligodendrocyte generation declined dramatically with age, this decline was partially reversed by growth factor infusion. Notably, co-infusion of EGF and HB-EGF increased oligodendrocyte regeneration twofold in some regions of the corpus callosum. Our results shed light on the beneficial effects of EGF and HB-EGF for increasing the contribution of NPCs to remyelination and indicate their therapeutic potential to combat the negative effects of aging upon remyelination efficacy.

Rejuvenation of Regeneration in the Aging Central Nervous System.

Microglia Impede Oligodendrocyte Generation in Aged Brain

Senescent-like microglia limit remyelination through the senescence associated secretory phenotype

[Neuroscience] Remyelination in the Central Nervous System

Ageing impairs the regenerative capacity of regulatory T cells in mouse central nervous system remyelination

Remyelination in the CNS: from biology to therapy

Restoring Nuclear Entry of Sirtuin 2 in Oligodendrocyte Progenitor Cells Promotes Remyelination During Ageing

Innate immune training restores pro-reparative myeloid functions to promote remyelination in the aged central nervous system

HB-EGF and EGF infusion following CNS demyelination mitigates age-related decline in regeneration of oligodendrocytes from neural precursor cells originating in the ventricular-subventricular zone

Niacin-mediated rejuvenation of macrophage/microglia enhances remyelination of the aging central nervous system

Cellular rejuvenation protects neurons from inflammation mediated cell death

Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination

Regenerative Capacity of Macrophages for Remyelination

M2 Microglia and Macrophages Drive Oligodendrocyte Differentiation During CNS Remyelination

Remyelination in humans due to a retinoid-X receptor agonist is age-dependent

Glial aging and its impact on central nervous system myelin regeneration

Aging compromises oligodendrocyte precursor cell maturation and efficient remyelination in the monkey brain

Regulatory T cells promote myelin regeneration in the central nervous system

Accelerated Remyelination During Inflammatory Demyelination Prevents Axonal Loss and Improves Functional Recovery

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

Strategies for myelin regeneration: lessons learned from development